FORMULATION AND IN VITRO CHARACTERIZATION OF IBRUTINIB EXTENDED RELEASE TABLETS

The aim of the present study was to develop extended release formulation of Ibrutinib to maintain constant therapeutic levels of the drug for over 12 hrs. HPMC K100M, HPMC (K4M) and Carbopol 71 G were employed as polymers. All the formulations were passed various physicochemical evaluation parameters and they were found to be within limits. Whereas from the dissolution studies it was evident that the formulation (F6) showed better and desired drug release pattern i.e., 98.85% in 12 hours. It contains the HPMC (K4M) as Extended release material. It followed peppas release kinetics mechanism. Keywords: Ibrutinib, Extended release system.